3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Polycystic Ovary Syndrome
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mycosis Fungoides
1
Menstruation Disturbances
1
Lymphoma
1
Hyperandrogenism
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn